Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AMRI in pact with Proteros Biostructures
Under the agreement, AMRI will combine its discovery and development capabilities with Proteros’ structural biology services to offer better services to the life sciences industry worldwide. Proteros is
Under the agreement, AMRI will combine its discovery and development capabilities with Proteros’ structural biology services to offer better services to the life sciences industry worldwide. Proteros is
Out of all licensed products, some are the US Food and Drug Administration (FDA) approved drugs while rest are unapproved. As per the terms of the agreement, Atley
In the study, the companies have randomized around 679 patients who are suffering from early-stage Parkinson’s disease. The companies will assess the safety and efficacy of two dose
The double blinded, placebo-controlled, single center and randomized trial aims to establish the dosage level of the vaccine while assessing the immugenicity and safety of EV71. The company
As per the terms of the amended agreement, Meda will be responsible to pay a sum of $45m to Medivir for transferring of all rights to the product
The current investment will ramp up the company’s R&D of multi-specific therapeutics. Eli Lilly intends to recruit biochemist and biologists to support its R&D for multi-specific drugs that
Stepan said the acquired product lines will be integrated into Stepan’s Food and Health Specialties business, which will be renamed Stepan Lipid Nutrition. Lipid Nutrition claims Clarinol conjugated
The FDA has also given permission for commencing Phase 1 trials with NRI-ANA as a treatment for an acute neuropathic pain condition using molecular skin penetration enhancers identified
The filing of the application is supported by the results of two Phase 3 trials, VIEW 1 and VIEW 2, conducted in Europe, Japan and other countries. The
Tibotec will be responsible for the formulation, manufacturing, registration, distribution and commercialization of the cobicistat and Prezista fixed-dose combination worldwide. Gilead is responsible to develop, manufacture and commercialize